Last reviewed · How we verify
Taxotere, Cisplatin, Afatinib
Taxotere, Cisplatin, Afatinib is a Small molecule drug developed by Groupe Oncologie Radiotherapie Tete et Cou. It is currently in Phase 1 development.
At a glance
| Generic name | Taxotere, Cisplatin, Afatinib |
|---|---|
| Sponsor | Groupe Oncologie Radiotherapie Tete et Cou |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
- Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taxotere, Cisplatin, Afatinib CI brief — competitive landscape report
- Taxotere, Cisplatin, Afatinib updates RSS · CI watch RSS
- Groupe Oncologie Radiotherapie Tete et Cou portfolio CI
Frequently asked questions about Taxotere, Cisplatin, Afatinib
What is Taxotere, Cisplatin, Afatinib?
Taxotere, Cisplatin, Afatinib is a Small molecule drug developed by Groupe Oncologie Radiotherapie Tete et Cou.
Who makes Taxotere, Cisplatin, Afatinib?
Taxotere, Cisplatin, Afatinib is developed by Groupe Oncologie Radiotherapie Tete et Cou (see full Groupe Oncologie Radiotherapie Tete et Cou pipeline at /company/groupe-oncologie-radiotherapie-tete-et-cou).
What development phase is Taxotere, Cisplatin, Afatinib in?
Taxotere, Cisplatin, Afatinib is in Phase 1.